Evaluation of Magnetic Fields to Treat Fibromyalgia
Primary Purpose
Fibromyalgia
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
magnetic therapy protocol A
magnetic therapy Protocol B
placebo therapy
Sponsored by
About this trial
This is an interventional treatment trial for Fibromyalgia focused on measuring Fibromyalgia, Pain associated with Fibromyalgia
Eligibility Criteria
Inclusion Criteria:
- Current diagnosis of fibromyalgia made by the study Principal Investigator (PI) according to the American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia.
- Rating of current Degree of Pain on the 0-10 Numeric Pain Intensity Scale of 4 or greater.
- Subject's use of pain relief medication(s) has been stable over the past 30 days, and subject is willing and able to maintain pre-existing use of pain relief medication(s) as his or her sole pain relief medication use, as needed, throughout study participation.
- Subject's use of insomnia medication(s) has been stable over the past 30 days, and subject is willing and able to maintain this existing use of insomnia medication(s) as his or her sole insomnia relief medication(s), as needed, throughout study participation.
- Subject has been on current (or no) medication regimen, unchanged for at least 30 days prior to study enrollment, and is willing and able to maintain that regular medication regimen, unchanged, throughout study participation.
- Willing and able to refrain from use of tender point injections throughout study participation.
- Willing and able to abstain from partaking in other/new treatments to improve fibromyalgia symptoms during study participation.
- Adequate contraceptive measures for female subjects. > 18 years of age or older.
- Male or female.
Exclusion Criteria:
- Any factors that might prevent the subject from completing a full course of therapy with the Resonator™ device, or from attending any of the scheduled study visits, or from completing any of the study measures.
- Subject suffers from co-existent chronic pain condition(s) of non-fibromyalgia origin, such as osteoarthritis, low back pain, neck pain, painful diabetic neuropathy and postherpetic neuropathic pain, that cannot be distinguished in severity and/or in type/sensation of pain from the pain originating from the subject's condition of fibromyalgia.
- Any other significant comorbidities that might impact the ability to evaluate the subject's satisfaction of the ACR 1990 Criteria for the Classification of Fibromyalgia, or for the subject to complete any of the study assessment tools.
- Tender point injections received within the prior one month.
- Current or past history of major psychiatric disturbance (e.g., schizophrenia, bipolar disorder, substance abuse).
- Known inflammatory rheumatic disease.
- Epilepsy/history of seizures/taking medication for epilepsy.
- HIV and other autoimmune disorders.
- Active cancer or treatment for cancer within last 6 months.
- Active infection(s).
- History of ECT
- Uncontrolled Hypertension.
- Advanced Pulmonary Disease.
- Unstable cardiac disease.
- Prosthetics or implants comprised of ferrous metals.
- Pacemakers, vagus nerve stimulators, or other functional electrical stimulators such as those commonly used for pain.
- Consumption of more than 21 alcoholic drinks per week.
- Pregnant, breast feeding, or planning pregnancy prior to end of study participation.
- Developmental disability or other cognitive impairment that would in the judgment of the PI impair adequate comprehension of the informed consent form or complete any of the study-related activities.
- Worker's compensation, receipt of disability or present/past litigation for monetary compensation pertaining to subject's fibromyalgia condition.
- Participation in other research within 30 days of study enrollment.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Active Comparator
Placebo Comparator
Arm Label
Resonator Protocol A
Resonator Protocol B
Inactive Resonator
Arm Description
Application of magnetic fields using the Resonator device Protocol B
Outcomes
Primary Outcome Measures
Mean Change in 3-recording Average of the Subjects Daily Pain Rating on the 0-10 Numeric Pain Intensity Scale.
Minimum scale value is '0' which represents 'no pain at all' and is the best outcome.
Maximum scale value is '10 which represents the 'worst pain imaginable' and is the worse outcome.
Secondary Outcome Measures
Full Information
NCT ID
NCT01262131
First Posted
December 14, 2010
Last Updated
June 6, 2011
Sponsor
pico-tesla Magnetic Therapies, LLC
1. Study Identification
Unique Protocol Identification Number
NCT01262131
Brief Title
Evaluation of Magnetic Fields to Treat Fibromyalgia
Official Title
A Randomized, Double-blind, Placebo-controlled Evaluation of the Application of Magnetic Fields Using the Resonator Device for the Treatment of Fibromyalgia: Pilot Study Protocol
Study Type
Interventional
2. Study Status
Record Verification Date
June 2011
Overall Recruitment Status
Completed
Study Start Date
December 2010 (undefined)
Primary Completion Date
May 2011 (Actual)
Study Completion Date
May 2011 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
pico-tesla Magnetic Therapies, LLC
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to see if a device called the Resonator can help to reduce pain and improve aspects of health and quality of life for people with fibromyalgia.
Detailed Description
The purpose of this pilot study is to assess the efficacy of the Resonator device as an adjunctive therapy to reducing pain and improving aspects of health and quality of life that are relevant to individuals with fibromyalgia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fibromyalgia
Keywords
Fibromyalgia, Pain associated with Fibromyalgia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
13 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Resonator Protocol A
Arm Type
Active Comparator
Arm Title
Resonator Protocol B
Arm Type
Active Comparator
Arm Description
Application of magnetic fields using the Resonator device Protocol B
Arm Title
Inactive Resonator
Arm Type
Placebo Comparator
Intervention Type
Device
Intervention Name(s)
magnetic therapy protocol A
Intervention Description
Application of magnetic fields using the Resonator device Protocol A
Intervention Type
Device
Intervention Name(s)
magnetic therapy Protocol B
Intervention Description
Application of magnetic fields using the Resonator device Protocol B
Intervention Type
Device
Intervention Name(s)
placebo therapy
Intervention Description
Application of inactive magnetic fields using the Resonator device
Primary Outcome Measure Information:
Title
Mean Change in 3-recording Average of the Subjects Daily Pain Rating on the 0-10 Numeric Pain Intensity Scale.
Description
Minimum scale value is '0' which represents 'no pain at all' and is the best outcome.
Maximum scale value is '10 which represents the 'worst pain imaginable' and is the worse outcome.
Time Frame
2 weeks (baseline to end of treatment)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Current diagnosis of fibromyalgia made by the study Principal Investigator (PI) according to the American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia.
Rating of current Degree of Pain on the 0-10 Numeric Pain Intensity Scale of 4 or greater.
Subject's use of pain relief medication(s) has been stable over the past 30 days, and subject is willing and able to maintain pre-existing use of pain relief medication(s) as his or her sole pain relief medication use, as needed, throughout study participation.
Subject's use of insomnia medication(s) has been stable over the past 30 days, and subject is willing and able to maintain this existing use of insomnia medication(s) as his or her sole insomnia relief medication(s), as needed, throughout study participation.
Subject has been on current (or no) medication regimen, unchanged for at least 30 days prior to study enrollment, and is willing and able to maintain that regular medication regimen, unchanged, throughout study participation.
Willing and able to refrain from use of tender point injections throughout study participation.
Willing and able to abstain from partaking in other/new treatments to improve fibromyalgia symptoms during study participation.
Adequate contraceptive measures for female subjects. > 18 years of age or older.
Male or female.
Exclusion Criteria:
Any factors that might prevent the subject from completing a full course of therapy with the Resonator™ device, or from attending any of the scheduled study visits, or from completing any of the study measures.
Subject suffers from co-existent chronic pain condition(s) of non-fibromyalgia origin, such as osteoarthritis, low back pain, neck pain, painful diabetic neuropathy and postherpetic neuropathic pain, that cannot be distinguished in severity and/or in type/sensation of pain from the pain originating from the subject's condition of fibromyalgia.
Any other significant comorbidities that might impact the ability to evaluate the subject's satisfaction of the ACR 1990 Criteria for the Classification of Fibromyalgia, or for the subject to complete any of the study assessment tools.
Tender point injections received within the prior one month.
Current or past history of major psychiatric disturbance (e.g., schizophrenia, bipolar disorder, substance abuse).
Known inflammatory rheumatic disease.
Epilepsy/history of seizures/taking medication for epilepsy.
HIV and other autoimmune disorders.
Active cancer or treatment for cancer within last 6 months.
Active infection(s).
History of ECT
Uncontrolled Hypertension.
Advanced Pulmonary Disease.
Unstable cardiac disease.
Prosthetics or implants comprised of ferrous metals.
Pacemakers, vagus nerve stimulators, or other functional electrical stimulators such as those commonly used for pain.
Consumption of more than 21 alcoholic drinks per week.
Pregnant, breast feeding, or planning pregnancy prior to end of study participation.
Developmental disability or other cognitive impairment that would in the judgment of the PI impair adequate comprehension of the informed consent form or complete any of the study-related activities.
Worker's compensation, receipt of disability or present/past litigation for monetary compensation pertaining to subject's fibromyalgia condition.
Participation in other research within 30 days of study enrollment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jerry I Jacobson, Ph.D, D.M.D.
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Evaluation of Magnetic Fields to Treat Fibromyalgia
We'll reach out to this number within 24 hrs